Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

The USDA says farmers have until 5 p.m. ET on Dec. 19 to apply. Those who qualify will receive payments by the end of ...

Marrakech, Morocco, 9th Dec 2025 – Morocco Excursion announced the introduction of an expanded 2025 program centered on tailor-made travel design across Morocco tours and Morocco desert tours. The ...

The comprehensive review Michael Alford promised when FSU announced it would retain Mike Norvell is now in full swing. Here's ...

Long the titan of prep schools in Los Angeles, with a reputation as an Ivy League feeder, Harvard-Westlake has seen the ...

Adeptify announces the launch of a leadership development program designed to strengthen managers’ clarity, capability, and ...

A new vision for passenger rail is on track in southeastern Wisconsin. The Milwaukee Area-Racine-Kenosha Passenger Rail has ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

This is a bimonthly column by Les Jebson, administrator of the Orthopedics and Sports Medicine Network at Prisma Health. This is the first installment. In the orchestration of an efficient orthopedic ...

I’ll have to say, of all the chaos and intense changes brought about by president Donald Trump’s second term, his so-called ...

Structure Therapeutics Inc. (NASDAQ: GPCR) shares shot up 100% to $68.95 after the company announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living ...